Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the transaction, the insider now owns 236,950 shares in the company, valued at $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Health Catalyst Price Performance
HCAT stock opened at $7.94 on Wednesday. The stock has a 50-day moving average price of $8.14 and a two-hundred day moving average price of $7.35. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $483.15 million, a PE ratio of -5.88 and a beta of 1.31.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. During the same period last year, the firm posted ($0.22) EPS. Health Catalyst's revenue was up 3.5% on a year-over-year basis. As a group, research analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.
Institutional Investors Weigh In On Health Catalyst
How to piss off your liberal friends… and profit from it
From Porter & Company | Ad
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X.
And people are slowly starting to wake up to the Deep State’s lies.
To get the full details on the fake “energy crisis” of America, watch this now
A number of institutional investors have recently added to or reduced their stakes in HCAT. Principal Financial Group Inc. boosted its position in shares of Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company's stock worth $188,000 after buying an additional 1,907 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock worth $96,000 after buying an additional 2,064 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company's stock worth $148,000 after buying an additional 2,164 shares during the period. Creative Planning boosted its position in shares of Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company's stock worth $174,000 after buying an additional 2,486 shares during the period. Finally, Quarry LP boosted its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after buying an additional 2,610 shares during the period. Hedge funds and other institutional investors own 85.00% of the company's stock.
Analyst Ratings Changes
Several research firms have recently commented on HCAT. Royal Bank of Canada raised their price target on Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a report on Thursday, November 7th. Evercore ISI raised their price target on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Citigroup raised their price target on Health Catalyst from $9.00 to $10.50 and gave the company a "buy" rating in a report on Wednesday, November 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Stephens raised their price target on Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.79.
View Our Latest Stock Report on Health Catalyst
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
